These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

257 related items for PubMed ID: 18971221

  • 21. Individualized rituximab treatment for relapsing neuromyelitis optica: a pediatric case report.
    He D, Yu Y, Yan W, Dai Q, Xu Z, Chu L.
    Pediatr Neurol; 2014 Aug; 51(2):255-8. PubMed ID: 25079575
    [Abstract] [Full Text] [Related]

  • 22. Prolonged Remission in Neuromyelitis Optica Following Cessation of Rituximab Treatment.
    Weinfurtner K, Graves J, Ness J, Krupp L, Milazzo M, Waubant E.
    J Child Neurol; 2015 Sep; 30(10):1366-70. PubMed ID: 25387545
    [Abstract] [Full Text] [Related]

  • 23. B cell survival in intragraft tertiary lymphoid organs after rituximab therapy.
    Thaunat O, Patey N, Gautreau C, Lechaton S, Fremeaux-Bacchi V, Dieu-Nosjean MC, Cassuto-Viguier E, Legendre C, Delahousse M, Lang P, Michel JB, Nicoletti A.
    Transplantation; 2008 Jun 15; 85(11):1648-53. PubMed ID: 18551073
    [Abstract] [Full Text] [Related]

  • 24. Cerebrospinal fluid high-mobility group box protein 1 in neuromyelitis optica and multiple sclerosis.
    Wang H, Wang K, Wang C, Xu F, Zhong X, Qiu W, Hu X.
    Neuroimmunomodulation; 2013 Jun 15; 20(2):113-8. PubMed ID: 23328212
    [Abstract] [Full Text] [Related]

  • 25. [Neurofilament protein light in multiple sclerosis].
    Zhang Y, Li X, Qiao J.
    Zhonghua Yi Xue Za Zhi; 2007 Oct 23; 87(39):2745-9. PubMed ID: 18167263
    [Abstract] [Full Text] [Related]

  • 26. In vivo labeling of blood T cells: rapid traffic into cerebrospinal fluid in multiple sclerosis.
    Hafler DA, Weiner HL.
    Ann Neurol; 1987 Jul 23; 22(1):89-93. PubMed ID: 3498435
    [Abstract] [Full Text] [Related]

  • 27. Cerebrospinal fluid T cell clones from patients with multiple sclerosis: recognition of idiotopes on monoclonal IgG secreted by autologous cerebrospinal fluid B cells.
    Holmøy T, Fredriksen AB, Thompson KM, Hestvik AL, Bogen B, Vartdal F.
    Eur J Immunol; 2005 Jun 23; 35(6):1786-94. PubMed ID: 15864781
    [Abstract] [Full Text] [Related]

  • 28. CSF chemokine levels in relapsing neuromyelitis optica and multiple sclerosis.
    Narikawa K, Misu T, Fujihara K, Nakashima I, Sato S, Itoyama Y.
    J Neuroimmunol; 2004 Apr 23; 149(1-2):182-6. PubMed ID: 15020078
    [Abstract] [Full Text] [Related]

  • 29. Immune surveillance of the human central nervous system (CNS): different migration pathways of immune cells through the blood-brain barrier and blood-cerebrospinal fluid barrier in healthy persons.
    Kleine TO, Benes L.
    Cytometry A; 2006 Mar 23; 69(3):147-51. PubMed ID: 16479603
    [Abstract] [Full Text] [Related]

  • 30. Multiple sclerosis: activated cells in cerebrospinal fluid in acute exacerbations.
    Noronha A, Richman DP, Arnason BG.
    Ann Neurol; 1985 Dec 23; 18(6):722-5. PubMed ID: 3841270
    [Abstract] [Full Text] [Related]

  • 31. Effective suppression of cerebrospinal fluid B cells by rituximab and cyclophosphamide in progressive multiple sclerosis.
    Petereit HF, Rubbert A.
    Arch Neurol; 2005 Oct 23; 62(10):1641-2; author reply 1642. PubMed ID: 16216954
    [No Abstract] [Full Text] [Related]

  • 32. Elevated cerebrospinal fluid uric acid during relapse of neuromyelitis optica spectrum disorders.
    Shu Y, Li H, Zhang L, Wang Y, Long Y, Li R, Qiu W, Lu Z, Hu X, Peng F.
    Brain Behav; 2017 Jan 23; 7(1):e00584. PubMed ID: 28127508
    [Abstract] [Full Text] [Related]

  • 33. Rituximab for myasthenia gravis: three case reports and review of the literature.
    Stieglbauer K, Topakian R, Schäffer V, Aichner FT.
    J Neurol Sci; 2009 May 15; 280(1-2):120-2. PubMed ID: 19272616
    [Abstract] [Full Text] [Related]

  • 34. Rituximab is effective in the treatment of refractory ophthalmic Wegener's granulomatosis.
    Taylor SR, Salama AD, Joshi L, Pusey CD, Lightman SL.
    Arthritis Rheum; 2009 May 15; 60(5):1540-7. PubMed ID: 19404964
    [Abstract] [Full Text] [Related]

  • 35. A review of the current use of rituximab in autoimmune diseases.
    Gürcan HM, Keskin DB, Stern JN, Nitzberg MA, Shekhani H, Ahmed AR.
    Int Immunopharmacol; 2009 Jan 15; 9(1):10-25. PubMed ID: 19000786
    [Abstract] [Full Text] [Related]

  • 36. Long-term B-lymphocyte depletion with rituximab in patients with relapsing-remitting multiple sclerosis.
    Stüve O, Leussink VI, Fröhlich R, Hemmer B, Hartung HP, Menge T, Kieseier BC.
    Arch Neurol; 2009 Feb 15; 66(2):259-61. PubMed ID: 19204165
    [Abstract] [Full Text] [Related]

  • 37. Immunologic and clinical responses to rituximab in a child with opsoclonus-myoclonus syndrome.
    Pranzatelli MR, Tate ED, Travelstead AL, Longee D.
    Pediatrics; 2005 Jan 15; 115(1):e115-9. PubMed ID: 15601813
    [Abstract] [Full Text] [Related]

  • 38. [B-lymphocytes in multiple sclerosis: studies concerning their levels in the blood and cerebrospinal fluid].
    Poloni M, Piovella F, Nappi G, Bazza D.
    Boll Ist Sieroter Milan; 1978 Jan 31; 56(6):597-602. PubMed ID: 305251
    [Abstract] [Full Text] [Related]

  • 39. Beneficial effect of rituximab monotherapy in multifocal motor neuropathy.
    Stieglbauer K, Topakian R, Hinterberger G, Aichner FT.
    Neuromuscul Disord; 2009 Jul 31; 19(7):473-5. PubMed ID: 19467601
    [Abstract] [Full Text] [Related]

  • 40. Peripheral B cell depletion and central proinflammatory cytokine reduction following repeated intrathecal administration of rituximab in progressive Multiple Sclerosis.
    Studer V, Rossi S, Motta C, Buttari F, Centonze D.
    J Neuroimmunol; 2014 Nov 15; 276(1-2):229-31. PubMed ID: 25175066
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.